Managing the negative regulation of Sirtuins in a murine model of premature ovarian failure: focusing on the key roles of antioxidants
Nasab SE., Shahhoseini M., Tavana S.
Narrative Review, published in J Ovarian Res (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Ovarian Res (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41272836
- PMCID
- PMC12639781
- DOI
- 10.1186/s13048-025-01821-0
Abstract (original English)
One of the most common side effects of chemotherapy is premature ovarian failure (POF) in women younger than 40. POF is linked to higher levels of gonadotropin hormones, lower levels of estradiol, and increased apoptosis and follicular atresia, all of which lower the quality of fertility and eventually make women unable to have children. There have been more and more reports since 1981 of different treatments that can protect against ovarian damage caused by chemotherapy. However, it is still challenging to find effective fertility-preserving measures for treating POF. Many of the newly proposed or developing chemotherapy treatments and radiotherapy-induced premature ovarian failure have shown limited efficacy or are associated with side effects, and their ability to fully restore ovarian function remains uncertain. However, the use of antioxidants to treat premature ovarian failure is a more effective method with fewer side effects than the recommended treatment methods. Antioxidants reduce symptoms of premature ovarian failure by affecting histone-modifying genes, especially the Sirtuin family, which function as redox environment sensors in granulosa cells and regulate the expression of downstream genes such as FOXO3a, P53, NF-κB, NRF2, and PGC-1a. This study aims to investigate how different treatments, especially antioxidants, can reactivate Sirtuin family genes to help wit
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.